Dingdang Health Technology Group Ltd. (HK:9886)
:9886
Want to see HK:9886 full AI Analyst Report?
Top Page
Dingdang Health Technology Group Ltd.
(9886)
Select Model
Select Model
Rating:62Neutral
Price Target:
HK$1.00
▼(-7.41% Downside)
Action:N/A
Date:04/29/26
The score is driven primarily by improving financial performance in 2025 (strong revenue rebound, better margins, and positive operating/free cash flow), supported by constructive technical momentum (price above key moving averages with positive MACD). The rating is held back by continued net losses and a negative P/E, which limits valuation support and underscores remaining execution risk.
Positive Factors
Revenue & Margin Recovery
A sharp revenue rebound and improving gross margin indicate the O2O pharmacy model is regaining scale and improving unit economics. Sustained top-line growth with margin expansion supports a credible path to profitability, stronger cash conversion and improved competitive positioning over the medium term.
Negative Factors
Residual Unprofitability
Despite progress, recurring net losses and negative ROE indicate the company has not achieved sustainable profitability. Continued subpar bottom-line performance leaves earnings exposed to cost inflation, competitive pricing pressure, and delays the firm’s ability to self-fund growth without dilutive or debt financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue & Margin Recovery
A sharp revenue rebound and improving gross margin indicate the O2O pharmacy model is regaining scale and improving unit economics. Sustained top-line growth with margin expansion supports a credible path to profitability, stronger cash conversion and improved competitive positioning over the medium term.
Read all positive factors
Dingdang Health Technology Group Ltd. (9886) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.21B
Dividend YieldN/A
Average Volume (3M)4.91M
Price to Earnings (P/E)―
Beta (1Y)1.82
Revenue Growth4.75%
EPS Growth87.06%
CountryHK
Employees2,363
SectorHealthcare
Sector Strength45
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)-0.26
Shares Outstanding1,319,472,900
10 Day Avg. Volume8,114,443
30 Day Avg. Volume4,906,414
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)0.75
Price to Sales (P/S)0.26
P/FCF Ratio10.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.07
Revenue Forecast (FY)HK$6.85B
Dingdang Health Technology Group Ltd. Business Overview & Revenue Model
Company Description
Dingdang Health Technology Group Ltd. operates as a service provider in the digital retail pharmacy industry in the People's Republic of China. The company offers pharmaceutical retail and medical consultation services. Dingdang Health Technology ...
How the Company Makes Money
The company primarily makes money by selling pharmaceutical and healthcare-related products to consumers through an O2O retail model that combines online ordering with fulfillment from its pharmacy network and delivery operations. Key revenue stre...
Dingdang Health Technology Group Ltd. Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
67
Positive
Cash Flow
64
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.73B | 4.89B | 4.67B | 4.86B | 4.33B | 3.68B |
| Gross Profit | 1.60B | 1.72B | 1.54B | 1.51B | 1.69B | 1.24B |
| EBITDA | -114.82M | -15.83M | -161.59M | -73.35M | -280.87M | -613.63M |
| Net Income | -343.68M | -49.02M | -376.50M | -225.81M | -2.83B | -1.58B |
Balance Sheet | ||||||
| Total Assets | 2.89B | 2.84B | 2.63B | 3.06B | 3.70B | 3.60B |
| Cash, Cash Equivalents and Short-Term Investments | 1.36B | 1.12B | 1.22B | 1.33B | 1.35B | 1.55B |
| Total Debt | 263.13M | 304.01M | 152.61M | 140.21M | 163.14M | 4.81B |
| Total Liabilities | 1.22B | 1.16B | 952.45M | 1.03B | 1.23B | 6.77B |
| Stockholders Equity | 1.66B | 1.66B | 1.66B | 2.24B | 2.19B | -2.61B |
Cash Flow | ||||||
| Free Cash Flow | 78.08M | 122.54M | -36.45M | -25.82M | -264.87M | -408.32M |
| Operating Cash Flow | 101.81M | 154.59M | -11.35M | -5.24M | -230.00M | -372.99M |
| Investing Cash Flow | -654.21M | -811.00M | 156.96M | 104.32M | -353.42M | 306.63M |
| Financing Cash Flow | -105.58M | -109.18M | -121.37M | -130.54M | 232.90M | 1.27B |
Dingdang Health Technology Group Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | HK$3.12B | 11.73 | 6.65% | 5.90% | 8.92% | 9.50% | |
74 Outperform | HK$29.35B | 16.51 | 19.93% | 1.84% | -0.47% | -11.25% | |
62 Neutral | HK$1.21B | ― | -11.92% | ― | 4.75% | 87.06% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | HK$497.79M | -20.28 | -10.69% | 1.72% | -3.49% | -1567.01% | |
48 Neutral | HK$940.99M | 92.73 | -12.38% | ― | 52.36% | ― | |
42 Neutral | HK$239.23M | -1.59 | 76.98% | ― | ― | ― |
* Healthcare Sector Average
HK:9886
Dingdang Health Technology Group Ltd.
0.93
0.57
158.33%
HK:0399
Innovative Pharmaceutical Biotech
0.07
-0.13
-64.04%
HK:0157
Natural Beauty Bio-Technology
0.47
-0.03
-6.00%
HK:6601
Cheerwin Group Limited
2.34
-0.14
-5.57%
HK:2138
EC Healthcare
0.42
-0.20
-32.26%
HK:2367
Giant Biogene Holding Co. Ltd.
28.00
-51.91
-64.96%
Dingdang Health Technology Group Ltd. Corporate Events
Dingdang Health Sets 2026 AGM to Approve Results, Board and New Share Mandate
Apr 24, 2026
Dingdang Health Technology Group Ltd. has called its annual general meeting for June 23, 2026 in Beijing, where shareholders will vote on adopting the audited consolidated financial statements for the year ended December 31, 2025 and receive repor...
Dingdang Health Narrows 2025 Loss and Turns to Adjusted Profit Amid China’s Digital Health Push
Mar 20, 2026
Dingdang Health Technology Group reported 2025 revenue of RMB4.89 billion, up 4.7% year on year, as China’s “Healthy China 2030” agenda and Internet-plus healthcare policies continued to expand the digital health market. The comp...
Dingdang Health Moves to Enable Virtual Shareholder Meetings via Charter Amendments
Mar 20, 2026
Dingdang Health Technology Group Ltd. plans to adopt a fifth amended and restated memorandum and articles of association to modernize its corporate governance framework. The changes are aimed at enabling shareholders to attend and participate in g...
Dingdang Health Sets March 20 Board Meeting to Approve 2025 Results
Mar 10, 2026
Dingdang Health Technology Group Ltd. has scheduled a board meeting for March 20, 2026, to review and approve its annual results for the financial year ended December 31, 2025. The board will also consider whether to recommend a final dividend, a ...
Dingdang Health Signals Major Loss Reduction and Return to Adjusted Profit in 2025
Feb 20, 2026
Dingdang Health Technology Group Ltd. expects its net loss for 2025 to narrow by more than 80% from the RMB380 million reported in 2024, driven largely by a sharp reduction in impairment charges on goodwill and other intangible assets, as well as ...
Dingdang Health Announces Board Reshuffle With New Executive Director
Feb 16, 2026
Dingdang Health Technology Group Ltd. announced leadership changes effective February 16, 2026, with executive director and vice president Yu Lei resigning from all positions in the group for personal career reasons. The board noted that Yu has no...
Dingdang Health Defines Board and Committee Lineup to Bolster Governance
Feb 16, 2026
Dingdang Health Technology Group Ltd. has outlined the composition of its board of directors, naming Yang Wenlong as chairman and president alongside four other executive directors, one non-executive director and three independent non-executive di...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.